After being diagnosed with Parkinson's disease at 50, Janice Hall felt her tremors get worse. Three years after being diagnosed she could "feel a kind of fluttering" that her medication could not stop ...
In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on AbbVie (ABBV – Research Report), with a ...
AbbVie should report strong Q3 2024 results next week and increase the full-year guidance. Explore more details here.
The U.S. Food and Drug Administration has approved AbbVie's Vyalev (foscarbidopa and foslevodopa) for adults living with ...
David Risinger, an analyst from Leerink Partners, maintained the Hold rating on AbbVie (ABBV – Research Report). The associated price ...
Zacks.com on MSN19h
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should KnowAbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Equities research analysts at Zacks Research reduced their Q3 2024 earnings estimates for AbbVie in a research note issued on ...
Bernstein has recently initiated AbbVie Inc (ABBV) stock to Mkt Perform rating, as announced on October 17, 2024, according to Finviz. Earlier, on June 5, 2024, HSBC Securities had raised the stock ...
Valuation metrics show AbbVie to be only slightly undervalued based on FY 2025 projections. Read why I'm neutral on ABBV ...
From Fortune 500 firms to startups, Crain's exclusive list reveals the Chicago-area companies inventing new ways of doing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback